Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion

Sino Biopharmaceutical's stock rose 8.4% after announcing a $358 million upfront deal with Boehringer Ingelheim for six oncology programs, with potential $7 billion in milestones. The agreement is the company's largest licensing deal by value. The news also boosted the Hong Kong pharma sector and the Hang Seng Index.

Boehringer Ingelheim licensed six oncology programs from Sino Biopharmaceutical for $358M upfront, with $7B in potential milestones. Nxera Pharma licensed an EP4 agonist to AbbVie for $100M upfront, with $1.37B in potential milestones. Both deals highlight pharma's reliance on external innovation.

Sino Biopharmaceutical and Boehringer Ingelheim agreed to develop six preclinical cancer programs, with $7B in potential milestone payments. Sino will receive $358M upfront and lead early trials, while Boehringer may obtain exclusive rights post-milestones.

Oracle terminated a $7B AI chip leasing deal with Tencent, according to the Financial Times. US and Chinese officials reportedly pressured both companies to cancel the agreement, which would have provided Tencent with up to 100,000 AI chips over five years. The cancellation highlights increasing restrictions on Chinese access to advanced chips, both directly and through overseas infrastructure.

Rocket Lab, a U.S.-based company with significant operations in New Zealand, launched satellites for HawkEye 360 and undisclosed Pentagon missions. The satellites are used for signals intelligence and defense, with Rocket Lab securing a $190M contract for hypersonic test flights. The company is expanding its role in U.S. space warfare, supported by the New Zealand government and investors.

Riot Platforms sold 8,962 BTC to fund data-center development and repay debt, leaving 2,418 BTC. The sale was 3.7 times its remaining BTC balance, marking a significant shift in its crypto treasury strategy.